The Off-Key Bard
History

This Day in History — Putting the Power of Birth Control in a Pill

On this day in 1951

On October 15, 1951, 26-year-old chemist Luis Miramontes synthesized norethindrone at Syntex in Mexico City, a molecule central to the birth-control pill.

The Off-Key Bard enters a chemistry laboratory in Mexico City in 1951. Glassware covers the workbenches, handwritten formulas fill laboratory notebooks, and a young researcher is working through a complicated sequence of chemical reactions. He isn't building a machine, launching a rocket, or developing a computer. He is attempting to create a molecule.

"A chemical compound small enough to fit inside a pill—but powerful enough to help change the course of human reproduction."

On October 15, 1951, 26-year-old Mexican chemist Luis Ernesto Miramontes Cárdenas completed the synthesis of norethindrone, a synthetic hormone that would become one of the foundational ingredients of modern oral contraceptives. Working at Syntex Laboratories in Mexico City under the supervision of Carl Djerassi and the direction of George Rosenkranz, Miramontes carried out the final step of the synthesis and recorded it in his laboratory notebook. It was a breakthrough that would eventually give millions of women a new means of controlling whether and when they became pregnant.

The significance of that October day would not become apparent for nearly another decade, and the distinction is essential to the story. The researchers had made oral hormonal contraception chemically possible. They had not yet produced the birth-control pill.

A Problem of Chemistry

For centuries, people had searched for ways to prevent pregnancy, from barrier methods and herbal preparations to withdrawal and fertility awareness. Some offered real protection; others were unreliable or dangerous. By the early 20th century, condoms and diaphragms were available, but reliable contraception remained out of reach for many because of cost, legal restrictions, medical barriers, and social attitudes. In the United States, the Comstock Act of 1873 had barred the mailing of materials considered obscene, including contraceptive information and devices, and related state laws added more obstacles.

Reproductive health advocates challenged those restrictions for decades. Among them was Margaret Sanger, a prominent campaigner for contraception and family-planning information. Her legacy is complicated, including documented involvement with the eugenics movement, but her advocacy helped generate political and financial support for research into new methods.

The science was just as hard. Physicians knew that the ovaries produce estrogen and progesterone, which influence ovulation and prepare the uterus for pregnancy, and that high hormone levels during pregnancy help prevent another ovulation. Researchers began to ask whether that natural effect could be reproduced with medication. If a woman could take a hormone that reliably suppressed ovulation, pregnancy might be prevented without a barrier device or a procedure at the time of intercourse.

The chemistry was the obstacle. Natural progesterone is poorly suited to ordinary oral use: when swallowed, much of it is rapidly processed by the digestive system and liver before it can act. Researchers needed a molecule that imitated progesterone's biological activity but still worked when taken by mouth. And that required new chemistry.

Why Mexico

This is where Mexico became a surprising center of pharmaceutical innovation. Chemists in the 1940s had learned to make steroid hormones from compounds extracted from certain plants, including Mexican yams of the genus Dioscorea. Those plants contained diosgenin, a naturally occurring steroid that could serve as a starting material for valuable hormones. American chemist Russell Marker had pioneered turning diosgenin into progesterone, and in 1944 he, Emeric Somlo, and Federico Lehmann formed Syntex in Mexico City. Marker left the company the following year, but Syntex remained a center of research into affordable ways to make steroid hormones.

The company drew talented chemists, including Carl Djerassi, an Austrian-born chemist who had emigrated to the United States to escape Nazi persecution, and worked with research director George Rosenkranz on an ambitious program of steroid chemistry. Their goal was powerful, orally active hormones that could treat reproductive disorders and other conditions.

One of the young scientists in the group was Luis Miramontes. Born in 1925 in Tepic, Mexico, he studied chemical engineering at the National Autonomous University of Mexico (UNAM) and was doing his undergraduate thesis work at the Syntex laboratory when he made the synthesis. By 1951 the team was investigating how structural changes to natural hormones could improve their activity, since even a small change to a molecule can dramatically alter how it interacts with receptors or survives metabolism. They needed a compound that behaved like progesterone but stayed potent when swallowed. Their target belonged to a class of chemicals called progestins.

October 15, 1951

On October 15, 1951, Miramontes completed the final step in the synthesis of a compound known chemically as 19-nor-17α-ethynyltestosterone, better known as norethindrone or norethisterone. The key final step was adding a carbon-carbon triple bond to the steroid framework. By modifying the structure of the steroid, the team had produced a molecule with strong progesterone-like activity that could be effective when administered orally.

Miramontes documented the result in his signed laboratory notebook, which is why October 15 is one of those rare scientific anniversaries for which we can identify the date of a critical laboratory achievement. Syntex filed a patent application the following month, naming Miramontes, Djerassi, and Rosenkranz as co-inventors. Later biological testing confirmed that norethindrone had powerful oral progestational activity.

From Compound to Pill

Whether the compound could prevent pregnancy was a separate question, and it depended on researchers elsewhere. In the early 1950s, reproductive biologist Gregory Pincus, working at the Worcester Foundation for Experimental Biology in Massachusetts with Min Chueh Chang, was pursuing exactly that. In 1953, Margaret Sanger and the philanthropist and women's rights advocate Katharine McCormick asked Pincus to develop a birth-control pill, and McCormick's funding paid for the early work. Pincus and Chang showed that progesterone could stop ovulation in animals, and fertility specialist John Rock ran early human trials with Pincus in Massachusetts.

A competing company, G. D. Searle, made another synthetic progestin, norethynodrel, through work by chemist Frank Colton. Norethynodrel is the progestin Pincus chose for the first pill, not Syntex's norethindrone, though the two compounds are closely related: stomach acid converts norethynodrel into norethindrone.

Large-scale human trials began in April 1956 in Río Piedras, a suburb of San Juan, Puerto Rico. Pincus chose the island partly because attitudes toward contraception were more tolerant there and because the work was kept away from anti-birth-control activists in Massachusetts. The first Puerto Rico study enrolled 221 married women from a low-income housing development. None of the women who took the pill as directed became pregnant. But the trials, like others in Boston, Worcester, and Haiti, are now seen as ethically troubling. Participants were not always given adequate information about the experimental treatment, the studies took place amid stark social and economic inequality, and informed-consent standards were far weaker than today's. About 17 percent of the Puerto Rico participants had unpleasant reactions such as nausea and dizziness, and one woman died of congestive heart failure, which the researchers did not attribute to the pill. Early formulations carried far higher hormone doses than later ones.

In June 1957, the U.S. Food and Drug Administration approved Searle's Enovid for treating menstrual disorders. Then came the pivotal date. On May 9, 1960, the FDA announced that it had approved Enovid for contraception, with little fanfare. It was the first birth-control pill approved for contraceptive use in the United States, and its principal progestin was Searle's norethynodrel rather than the norethindrone synthesized at Syntex.

That distinction matters because modern oral contraception did not come from one chemist making one finished medication. It emerged from parallel advances in organic chemistry, reproductive biology, clinical testing, pharmaceutical development, and decades of advocacy. Miramontes, Djerassi, and Rosenkranz helped make hormonal contraception chemically possible. Pincus, Chang, Rock, and their colleagues showed how it could prevent ovulation. McCormick's money sustained the research, and a long political struggle had created pressure for access.

A Pill and What Followed

The pill changed the relationship between reproduction and everyday life. For the first time, many women gained access to a highly effective, reversible contraceptive that did not need to be used immediately before intercourse. Over time, reliable contraception became one factor supporting expanded educational and employment opportunities, changing family patterns, and greater reproductive autonomy. The pill did not produce those changes alone. Shifting laws, women's rights movements, economic developments, and changing cultural expectations all played roles. But it made new choices possible for millions of people.

It was never free of controversy. Debates over religion, reproductive rights, medical safety, and access accompanied its introduction and continue today. Early high-dose pills carried risks, including cardiovascular complications, and later research refined doses, improved formulations, and identified medical conditions that affect which hormonal contraceptives are appropriate. Modern oral contraceptives include combined estrogen-progestin pills and progestin-only pills, and norethindrone and related compounds remain in use in contraceptive products and in treatments for several reproductive health conditions.

The October 1951 achievement also deserves recognition for another reason. It was a significant contribution by Mexican scientists working in Mexico, at a time when major pharmaceutical discoveries were more often associated with laboratories in the United States or Europe. Miramontes was still a young researcher, and his role has often been overshadowed by the better-known names tied to the commercial pill. Historians have noted that the story was shaped largely by Djerassi, who is often called the "Father of the Pill." Miramontes never received a Ph.D. despite completing the requirements, later became a director at Searle, and died in 2004. In 2010, the president of the Mexican Academy of Sciences ranked his work among Mexico's top three scientific contributions.

"Within a flask, a molecule grew,
A path to choices medicine knew.
From careful notes and chemistry's art,
A wider world of choice could start."

The history of the birth-control pill is more complex than the story of a single invention. It involved decades of scientific research, political struggle, medical experimentation, financial support, and changing attitudes toward women's health and reproductive freedom, along with difficult ethical questions that deserve recognition beside its achievements. But the chemical milestone of October 15, 1951 remains an essential part of that history.

On October 15, 1951, Luis Miramontes completed the synthesis of norethindrone within the Syntex team led by Djerassi and Rosenkranz, helping establish the chemistry behind modern oral contraception. A young scientist working in Mexico City could not have known the full medical and social implications of his work. Within a decade, oral contraception would be a reality for women in the United States, and the molecule he produced that October day had become part of the foundation for that change.

Sources

← Back to the Desk — History